Connect
MJA
MJA

Survival of patients with ruptured and non‐ruptured hepatocellular carcinoma

Natassia P Tan, Ammar Majeed, Stuart K Roberts, Paul J Gow, Penny Hey, Xianjun Mah, Mark Goodwin, Siddharth Sood, John Lubel, Amanda Nicoll, Anouk Dev, Sally J Bell and William W Kemp
Med J Aust 2020; 212 (6): 277-278. || doi: 10.5694/mja2.50483
Published online: 24 February 2020

Hepatocellular carcinoma (HCC) is causing an increasing number of deaths in Australia; the 5‐year survival rate from diagnosis is about 16%.1 Tumour rupture is a life‐threatening complication and the third most common cause of death (after tumour progression and liver failure) for people with HCC; mortality caused by rupture during the acute phase has been reported to be 25–75% in Asian countries.2,3 The poor prognosis is related to intraperitoneal haemorrhage and the potential for intraperitoneal metastases. Hypotheses about the cause of spontaneous rupture include rapid growth and necrosis, splitting of the overlying parenchyma or vessel erosion, increased intratumoral pressure with hepatic vein occlusion, and coagulopathy.2 Tumour size exceeding 50 mm and superficial location are risk factors for rupture.3

We investigated the impact of spontaneous HCC rupture on survival. All adult patients who presented with spontaneous HCC rupture to six tertiary referral hospitals in Melbourne between January 2007 and July 2018 were included in our retrospective case–control study. We extracted data for patients with non‐ruptured HCC (ratio, 3:1) from a Victorian prospective HCC database;4 the patients in the two groups were matched for age, sex, Barcelona Clinic Liver Cancer stage, and Model of End‐Stage Liver Disease score by propensity score matching. De‐identified data on baseline characteristics, management of rupture, and outcomes were extracted from patient medical records. Statistical analyses were conducted in SAS 9.4 and R 3.5.0. The study was approved by the Alfred Hospital Human Research Ethics Committee, which waived the requirement for informed consent (reference, 109/17).

The baseline characteristics of the two groups were similar (Box 1). At the end of the study period, median survival time was 1.3 years (95% confidence interval [CI], 0.8–1.9 years; range, 0–8.3 years) in the non‐rupture group and 1.7 years (95% CI, 0.9–4.4 years; range, 0–6.1 years) in the rupture group. Kaplan–Meier survival analysis (Box 2) did not indicate any significant difference in survival time between the groups (log rank P = 0.21). HCC rupture was not an independent predictor of mortality in a Cox proportional hazards regression analysis (hazard ratio, 0.72; 95% CI, 0.54–1.20).

The longer survival for our cohort of patients with ruptured HCC than in other studies may be explained by their having greater hepatic functional reserve and less evidence of vascular thrombus and extrahepatic invasion (Box 1) than reported for other study cohorts.2 Curative surgical management may also have improved survival. For 26 of 33 patients in the rupture group (79%), spontaneous rupture was the first indication of HCC; lead time bias or earlier consideration of therapy after managing the rupture were therefore possible. Nevertheless, our data indicate that tumour rupture may not be as important as other prognostic factors for survival.

Although our study encompassed ten years of data, the number of patients with ruptured HCC was small, consistent with the low incidence of rupture in Western countries (2–3%).5 Reporting and ascertainment bias were possible, as some patients may have died before reaching hospital or while undergoing confirmatory imaging. However, our study is the first in Australia to specifically examine the influence of spontaneous rupture as a prognostic factor in patients with HCC, using propensity matching to adjust for variables known to influence survival.

Given the potential for median survival times of more than 12 months, patients with ruptured HCC should be treated with the aim of long term survival. Larger prospective studies of the impact of HCC rupture on prognosis are warranted.

Box 1 – Characteristics of propensity score‐matched patients with ruptured or non‐ruptured hepatocellular carcinoma

 

Hepatocellular carcinoma

Ruptured

Non‐ruptured


Number of patients

33

99

Men

28 (85%)

83 (84%)

Age (years), median (IQR)

63.4 (42–86)

66.2 (27–91)

Etiology of hepatocellular carcinoma

 

 

 HBV

7 (21%)

10 (10%)

 HCV

7 (21%)

15 (15%)

 HBV/HCV co‐infection

1 (3%)

2 (2%)

 HBV/HCV/alcohol

0

1 (1%)

 HBV/alcohol

0

1 (1%)

 HCV/haemochromatosis

0

1 (1%)

 HCV/alcohol

2 (6%)

11 (11%)

 HCV/non‐alcoholic steatohepatitis

0

2 (2%)

 Alcohol

5 (15%)

21 (21%)

 Non‐alcoholic steatohepatitis/non‐alcoholic fatty liver disease

4 (12%)

8 (8%)

 Alcohol/haemochromatosis

0

1 (1%)

 Autoimmune hepatitis

0

1 (1%)

 Haemochromatosis

0

2 (2%)

 Primary biliary cholangitis

0

1 (1%)

 Idiopathic

7 (21%)

22 (22%)

Barcelona Clinic Liver Cancer stage

 

 

 A

5 (15%)

12 (12%)

 B

14 (42%)

39 (39%)

 C

13 (39%)

44 (44%)

 D

1 (3%)

4 (4%)

MELD score, median (IQR)

12 (6–28)

11 (6–29)

Tumour size (mm), median (IQR)

60 (12–160)

42 (20–180)

Albumin (g/L), median (IQR)

29 (20–40)

32 (14–52)

Alpha fetoprotein (ng/ml), median (IQR)

23 (1.4–77 232)

9.7 (0–70 920)

Bilirubin (μmol/L), median (IQR)

16 (5–140)

17 (5–89)

Creatinine (μmol/L), median (IQR)

85 (41–372)

92 (41–308)

International normalised ratio, median (IQR)

1.3 (0.9–3.7)

1.2 (0.9–5.0)

Follow‐up (years), median (IQR)

1.05 (0–6.9)

1.02 (0–8.7)

Deaths

19 (58%)

78 (79%)

Extrahepatic disease

 

NA

 None

20 (61%)

 

 Portal vein invasion

5 (15%)

 

 Porta hepatis extension

2 (6%)

 

 Extrahepatic metastases

6 (18%)

 

Number of tumours

 

NA

 1

12 (36%)

 

 2

8 (24%)

 

 3

3 (9%)

 

 4 or more

9 (27%)

 

Acute management for hepatocellular carcinoma rupture

 

 Conservative

12 (36%)

 

 Transarterial embolisation

13 (39%)

 

 Surgery

3 (9%)

 

 Transarterial embolisation/surgery

5 (15%)

 


HBV = hepatitis B virus; HCV = hepatitis C virus; IQR = interquartile range; MELD, Model of End‐Stage Liver Disease; NA = data not available. Missing data: * one patient; † 14 patients (maximum tumour size taken); ‡ six patients.

Box 2 – Kaplan–Meier survival analysis, by hepatocellular carcinoma rupture status*


*99 patients without rupture (78 deaths, 21 censored); 33 patients with rupture (19 deaths, 14 censored). Patients were censored at the date of their last tertiary centre visit or the date of their death. Log‐rank = 0.21.

Received 26 August 2019, accepted 28 October 2019

  • Natassia P Tan1
  • Ammar Majeed1,2
  • Stuart K Roberts1
  • Paul J Gow3
  • Penny Hey3
  • Xianjun Mah4
  • Mark Goodwin3
  • Siddharth Sood5
  • John Lubel4
  • Amanda Nicoll4
  • Anouk Dev6
  • Sally J Bell6
  • William W Kemp7

  • 1 Alfred Health, Melbourne, VIC
  • 2 Monash University, Melbourne, VIC
  • 3 Austin Hospital, Melbourne, VIC
  • 4 Eastern Health, Melbourne, VIC
  • 5 Royal Melbourne Hospital, Melbourne, VIC
  • 6 Monash Health, Melbourne, VIC
  • 7 The Alfred Hospital, Melbourne, VIC

Correspondence: n.tan@alfred.org.au

Competing interests:

No relevant disclosures.

  • 1. Carville KS, MacLachlan JH, Thursfield V, Cowie BC. Hepatocellular carcinoma over three decades in Victoria, Australia: epidemiology, diagnosis and trends, 1984–2013. Intern Med J 2018; 48: 835–844.
  • 2. Lai ECH, Lau WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 2006; 141: 191–198.
  • 3. Sahu SK, Chawla YK, Dhiman RK, et al. Rupture of hepatocellular carcinoma: a review of literature. J Clin Exp Hepatol 2019; 9: 245–256.
  • 4. Mgaieth S, Kemp W, Gow P, et al. Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: a large multicentre cohort study. J Viral Hepat 2017; 24: 982–989.
  • 5. Schwarz L, Bubenheim M, Zemour J, et al; FRENCH association. Bleeding recurrence and mortality following interventional management of spontaneous HCC rupture: results of a multicenter European study. World J Surg 2018; 42: 225–232.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.